Which guidelines underpin Quality by Design (QbD) and design space concepts, and what is their regulatory significance?

• A. ICH Q6B and Q7 only.
• B. ICH Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Development and manufacture of drug substances and products); they support a risk-based, science-led approach with regulatory flexibility within a defined design space.
• C. ICH Q5C and Q5D only.
• D. ICH Q2 and Q3 only.

Answer: (C)

Quality by Design and design space are built on a group of ICH guidelines that promote a science-based, risk-driven approach to pharmaceutical development and lifecycle management. The key references describe how product and process understanding should be advanced, how risks are identified and controlled, and how a formal quality system supports ongoing performance. Specifically, these guidelines establish that you should develop a robust design space—an approved multidimensional region of operation where process parameters can vary while still ensuring quality. Working within this space provides regulatory flexibility: changes that stay inside the design space and remain within the approved control strategy can often be justified without restarting the entire approval process, while still maintaining assurance of quality. Regulators expect a deep demonstration of understanding, a solid risk management framework, and a well-defined control strategy that ties process performance to product quality across the lifecycle. In short, QbD and design space are regulatory concepts that enable a science- and risk-based pathway to develop, manufacture, and continuously improve quality, with built-in flexibility aligned to the evidence and control strategy.